FDA nod for AADC deficiency gene therapy from PTC
The US Food and Drug Administration (FDA) has granted accelerated approval of PTC Therapeutics’ gene therapy for the treatment of AADC (aromatic L-amino acid decarboxylase) deficiency, making it the first-ever gene therapy approved in the USA that is directly administered to the brain.
PTC Therapeutics Gains Buy Rating Following FDA Approval of Groundbreaking Gene Therapy Kebilidi
Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC deficiency, is a significant milestone for the company.
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC deficiency treatment.
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder
Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene ... coats in turnaround plan 9:45 AM UTC · Updated ago Reuters, the news and media division of Thomson Reuters, is the world’s largest ...
PTC Therapeutics wins FDA nod for gene therapy
PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read more here.
PTC Therapeutics’ AADC deficiency gene therapy granted FDA approval
PTC Therapeutics (PTCT) announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever
PTC Therapeutics price target raised to $45 from $43 at Barclays
Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $43 and keeps an Equal Weight rating on the shares. After ...
Hosted on MSN15h
Multibagger Stock: PTC Industries surges over 275% in 2 years, achieves 3,200% growth in 4 years
Multibagger Stock: PTC Industries, an engineering component manufacturer, has experienced a remarkable surge in its share ...
Yahoo Finance9d
PTC to Report Q4 Earnings: Here's What Investors Should Know
For the quarter, PTC anticipates revenues to be between $598 million and $648 million. Non-GAAP earnings per share (EPS) are expected to be between $1.30 and $1.66. The Zacks Consensus Estimate ...
Reuters7d
PTC forecasts quarterly revenue below estimates on tight tech spending
Nov 6 (Reuters) - Industrial software maker PTC (PTC.O), opens new tab forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in demand for its industrial design ...
Balancing Growth Prospects and Regulatory Challenges: A Hold Rating on PTC Therapeutics
Joseph Schwartz, an analyst from Leerink Partners, reiterated the Hold rating on PTC Therapeutics (PTCT – Research Report). The ...
Yahoo Finance7d
PTC Inc.: Fiscal Q4 Earnings Snapshot
BOSTON (AP) — BOSTON (AP) — PTC Inc. (PTC) on Wednesday reported fiscal fourth-quarter profit of $126.5 million. The Boston-based company said it had profit of $1.04 per share. Earnings ...